Paper Details

  1. Home
  2. Paper Details

Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.

Author: DuvicM

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article reviews three new highly effective agents in the armamentarium for the treatment of cutaneous T-cell lymphoma: bexarotene gel, bexarotene capsules, and DAB(389)IL-2.
Paper Details　
Original Abstract of the Article :
Mycosis fungoides (MF), CD4(+) epidermotropic cutaneous T-cell lymphoma (CTCL), often arises as indolent, inflammatory, chronic, persistent patches and plaques. Conservative and sequential topical therapy patients have the same survival as patients treated with aggressive chemotherapy. Hence, until ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3816/clm.2000.s.010

データ提供：米国国立医学図書館（NLM）

Treatment Strategies for Cutaneous T-Cell Lymphomas

This review explores the treatment options for cutaneous T-cell lymphomas (CTCL), specifically mycosis fungoides (MF), and proposes algorithmic approaches for managing this challenging disease. It's like mapping out a complex journey through a desert, identifying different routes and strategies for navigating the terrain of cancer treatment.

Bexarotene: A New Topical Agent

The review highlights the effectiveness of bexarotene gel, a new topical retinoid X receptor retinoid, in resolving MF lesions. It's like discovering a powerful plant that can heal a specific type of wound in the desert, restoring balance to the affected area.

DAB(389)IL-2: A Targeted Therapy

The review also explores the use of DAB(389)IL-2, a targeted therapy effective in killing activated T cells, as a treatment option for more advanced CTCL. It's like finding a unique weapon that can specifically target a particular threat in the desert, minimizing collateral damage.

Dr.Camel's Conclusion

This review, like a seasoned desert guide providing navigational insights, offers valuable information about the treatment strategies for cutaneous T-cell lymphomas. It reminds us that finding the right path in the desert of cancer treatment requires careful consideration of different options, tailoring the journey to the specific needs of each patient.

Date :
  1. Date Completed 2002-01-23
  2. Date Revised 2019-11-05
Further Info :

Pubmed ID

11707865

DOI: Digital Object Identifier

10.3816/clm.2000.s.010

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.